Oct. 21, 2023, 7:20 pm by Alicia Powe Gateway Pundit
CVS is voluntarily removing over-the-counter cough and cold products from its shelves after a Food and Drug Administration advisory panel confirmed the active ingredients of America’s leading decongestive “medicines” do not work.
Millions who consume Dayquil, Sudafed, and other medications stocked on store shelves while looking for relief from a stuffy nose might as well be taking dummy pills, according to government experts who reviewed the latest research on the long-questioned drug ingredients.
Last month, 16 members of the FDA’s Nonprescription Drug Advisory Committee unanimously voted against the effectiveness of oral phenylephrine, the key ingredient contained in Sudafed, Mucinex, Allegra, Dayquill, and all the highest-selling decongestants included on a federal list of medicines deemed effective for over-the-counter pills and liquids.
Phenylephrine is also found in Tylenol for Colds and Flu Severe Day and night.
The products are safe but do nothing to alleviate nasal congestion, the panel determined.
A CVS spokesperson announced Thursday that the products containing phenylephrine are no longer available in stores nationwide.
“We are voluntarily removing certain oral cough and cold products that contain phenylephrine as the only active ingredient from CVS Pharmacy stores,” a CVS spokesperson announced Thursday. “Other oral cough and cold products will continue to be offered to meet consumer needs.
“We are aware of the FDA Advisory Committee’s position on oral phenylephrine (PE) and will follow direction from the FDA to ensure products we sell comply with all laws and regulations.”
The FDA hasn’t made any decision regarding the product’s effectiveness or distribution amid CVS’s decision to pull the products.
Instead, the agency encourages consumers to read the labels and make up their minds about the drug’s effectiveness.
“Consumers should always read the drug fact label to determine which ingredients are in a medication, as well as important warnings and directions for use,” the agency said. “Work closely with manufacturers to reformulate products as needed to help ensure availability of safe and effective products to treat symptoms of colds or allergies.”
If the FDA complies with its advisory panel’s recommendations, Johnson & Johnson, Bayer, and other drugmakers would be required to pull their oral medications containing phenylephrine from store shelves, a move that would force consumers to switch to the behind-the-counter pseudoephedrine products or phenylephrine-based nasal sprays and drops.
With only the drops and nasal sprays available, the FDA would have to work with drugstores, pharmacists, and other health providers to educate consumers about the remaining options for treating congestion, warns the panel of government advisors.
Studying phenylephrine at higher doses is not an option because it can push blood pressure to potentially dangerous levels, the committee told the FDA.
The common cold “medicines” remain on shelves at Walgreens and Rite Aid.
Executives at Walgreens are “closely monitoring the situation and actively partnering with the Walgreens Office of Clinical Integrity and suppliers on appropriate next steps,” a spokesperson for the pharmacy retail giant told FOX Business.
The FDA assembled its outside advisers to examine phenylephrine after researchers at the University of Florida petitioned the FDA to remove nearly all phenylephrine products based on numerous recent studies indicating they failed to outperform placebo pills in patients with cold and allergy congestion.
Alicia is an investigative journalist and multimedia reporter. Alicia's work is featured on numerous outlets including the Gateway Pundit, Project Veritas, Red Voice Media, World Net Daily, Townhall, and Media Research Center, where she uncovers fraud and abuse in government, media, Big Tech, Big Pharma, and public corruption. Alicia has a Bachelor of Science in Political Science from John Jay College of Criminal Justice. She served in the Correspondence Department of the George W. Bush administration and as a War Room analyst for the Rudy Giuliani Presidential Committee.
Click on the link below to go to the original article at the Gateway Pundit.